← Leaderboards
Jim Rotolo
Ceramide Therapeutics, Llc
$6,184,744
Attributed
$6,184,744
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2011–24$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,184,744 · 8
By mechanism
R44$3,429,465 · 2
R43$2,755,279 · 6
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoDoseIn VitroAffinityMediatingBaseTissuesCessation Of LifeCellsGenesPeptidesDesignCell SurvivalProteinsApoptosisSmall Business Innovation Research GrantMedicalBiological AvailabilityMalignant NeoplasmsMembraneCell DeathGeneticBindingEnzyme-Linked Immunosorbent Assay
Grant awards (14)
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer$632,111
R44 · FY2024 · CA · contact PI
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer$1,362,268
R44 · FY2023 · CA · contact PI
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer$803,479
R44 · FY2023 · CA · contact PI
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer$631,607
R44 · FY2022 · CA · contact PI
Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide$288,178
R43 · FY2022 · AI · contact PI
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer$409,295
R43 · FY2021 · CA · contact PI
Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide$299,860
R43 · FY2021 · AI · contact PI
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer$255,240
R43 · FY2020 · CA · contact PI
Single-chain antibody countermeasures for the Radiation GI Syndrome$101,021
R43 · FY2015 · AI · contact PI
Single-chain antibody countermeasures for the Radiation GI Syndrome$300,000
R43 · FY2014 · AI · contact PI
Neutralization of ceramide as a novel approach to specifically inhibit acute GvHD$223,891
R43 · FY2013 · AI · contact PI
Selection of an anti-ceramide mitigator of acute radiation toxicity of the GI tra$292,977
R43 · FY2012 · AI · contact PI
Neutralization of ceramide as a novel approach to specifically inhibit acute GvHD$284,820
R43 · FY2012 · AI · contact PI
Selection of an anti-ceramide mitigator of acute radiation toxicity of the GI tra$299,997
R43 · FY2011 · AI · contact PI